Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?
Recruiting
N/A
Interventional Study
Pulmonary Embolism
Hematopoiesis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 544 (estimated)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The clonal hematopoiesis of indetermined prognosis (CHIP) has been described as risk factor for juvenile atherosclerosis. Moreover, some of CHIP genes are responsible of myeloproliferative disorders. Venous thrombosis are frequent in these disorders. The purpose of this project is to determine if CHIP is frequent in unprovoked pulmonary embolism and could be part of the pathophysiology.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* For cases : Previous proximal unprovoked pulmonary embolism, negative thrombophilia screening.
* For control : Previous proximal provoked pulmonary embolism, negative thrombophilia screening.
Exclusion Criteria:
* Age superior to 65 years old,
* Active cancer
Contacts